R

Roche

Global pharmaceuticals and diagnostics company

International Product Manager

Full-TimeUpdated on 10/23/2026
$148k - $217.4k/yr+ Discretionary annual bonus
Junior
Bachelor's
Tucson, AZ, USA
In PersonPosition requires up to 30% fully reimbursed domestic and international travel.
ProductProduct Management

About the job

Requirements
  • A bachelor's degree or foreign equivalent in Engineering or a related field is required.
  • At least 3 years of experience in the offered job, as a Product Engineer, Product Specialist, or in a related position in the healthcare diagnostics industry is required.
  • At least 2 years of experience must include comprehensive knowledge of cross-portfolio in-vitro diagnostics solutions and integration of diverse diagnostic platforms within a clinical laboratory.
  • At least 2 years of experience must include advanced technical proficiency in in-vitro diagnostics systems and medical device architecture.
  • At least 2 years of experience must include international market expertise within the in-vitro diagnostics sector.
  • At least 2 years of experience must include field-based customer experience within the pathology diagnostics industry.
  • At least 2 years of experience must include managing high-level technical escalations and collaborating with research and development for product defect resolution.
  • At least 2 years of experience must include service performance analytics and technical key performance indicator optimization within a regulated clinical environment.
Responsibilities
  • Execute the global strategic roadmap for a diagnostic portfolio valued at $525 million.
  • Direct the development of technical and commercial marketing assets, including scientific publications, digital media, and international congress symposia.
  • Lead and prioritize cross-functional project teams incorporating research and development, manufacturing, and quality to drive product enhancements and mandatory technical modifications, ensuring engineering changes align with global commercial objectives.
  • Provide strategic direction and managerial oversight to 55 Regional Marketing and Sales Managers, ensuring local execution of product positioning and approving regional resource allocations.
  • Direct the international marketing budget, optimizing spending across global initiatives to support market penetration and return on investment.
  • Manage and influence global key opinion leaders and communication agencies to align scientific advocacy with the global brand strategy.
  • Serve as the primary strategic decision-maker within the International Business Team, directing cross-departmental decisions in supply chain, regulatory, and finance to protect portfolio profitability and market share.
  • Monitor customer requirements and platform performance data to justify and lead high-level technical specifications and quality improvement initiatives.
  • Coordinate global launch and promotional activities for new and existing in-vitro diagnostics platforms, preparing regional affiliates for market entry.
  • Drive global marketing strategies through affiliate companies, providing guidance on complex product issues and ensuring local plans meet global standards.
  • Participate in International Business Team and affiliate summits as the subject matter expert for pathology and diagnostic product lines.
  • Analyze global market trends and competitive landscapes to develop defense strategies and identify opportunities for portfolio expansion.
  • Participate in market research to monitor competitor activities and develop strategic responses to maintain global market leadership.
  • Travel up to 30% domestically and internationally; travel is fully reimbursed.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 26th, 2026
Zymeworks licenses ZW209 to Roche in deal worth up to $813M, with $55M upfront

Zymeworks has granted Roche exclusive worldwide rights to develop and commercialise ZW209, a DLL3-targeting trispecific T-cell engager. The deal brings $55.0 million upfront, up to $758.0 million in further milestones, and tiered royalties. Roche will take on most later development and commercialisation work. That fits Zymeworks' partnership-heavy, capital-light model, though future cash from ZW209 now depends largely on Roche meeting its own targets. The company also reported Phase 1 data for ZW191, an ovarian cancer antibody-drug conjugate. It showed activity across folate receptor alpha expression levels and a more favourable tolerability profile at 6.4mg/kg.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.